Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18-month extension study of intermittent intraputaminal GDNF infusions in Parkinson's disease
2013-001881-40Phase 2Completed
- Sponsor
- North Bristol NHS Trust
- Start
- Aug 2013
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glial cell line-derived neurotrophic factor in Parkinson's disease (PD), sponsored by North Bristol NHS Trust. Primary endpoint: Percentage change from baseline to end of treatment in practically defined OFF-state UPDRS motor score (Part III). Started Aug 2013; status: completed.
02
Drugs
glial cell line-derived neurotrophic factor
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2013-001881-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001881-40.